Semaglutide and Tirzepatide are two of the most studied peptides in metabolic research. Both target incretin pathways, but they differ fundamentally in receptor selectivity, molecular structure, and mechanism of action. This article breaks down the science behind each compound and what the published literature reveals.
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Targets | GLP-1 receptor (single agonist) | GLP-1 + GIP receptors (dual agonist) |
| Amino Acids | 31 amino acids | 39 amino acids |
| Half-Life | ~7 days | ~5 days |
| Molecular Weight | ~4,114 Da | ~4,810 Da |
| Administration | Once weekly | Once weekly |
| Fatty Acid Modification | C18 fatty di-acid | C20 fatty di-acid |
| Primary Research Focus | Metabolic regulation, appetite signalling | Metabolic regulation, dual-incretin signalling |
Semaglutide is a modified analogue of human glucagon-like peptide-1 (GLP-1). It binds selectively to the GLP-1 receptor, which is expressed in pancreatic beta cells, the central nervous system, the gastrointestinal tract, and the cardiovascular system.
Its key modifications include an amino acid substitution at position 8 (Aib for Ala) that confers resistance to DPP-4 enzymatic degradation, and a C18 fatty di-acid side chain attached via a linker at Lys26 that promotes albumin binding. This albumin binding extends the half-life to approximately 7 days, enabling once-weekly dosing.
At the cellular level, GLP-1 receptor activation stimulates cyclic AMP (cAMP) production, which enhances glucose-dependent insulin secretion, suppresses glucagon release, and activates satiety centers in the hypothalamus.
Tirzepatide is the first peptide to combine agonist activity at both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. Its 39 amino acid sequence is based on the native GIP sequence with modifications that confer GLP-1 receptor cross-reactivity.
The rationale for dual agonism is based on the complementary roles these incretins play. GIP and GLP-1 are both secreted from the gut after food intake and together account for 50-70% of postprandial insulin secretion. By activating both pathways simultaneously, tirzepatide engages a broader set of metabolic mechanisms than either incretin alone.
Key distinction: Semaglutide is a selective GLP-1 agonist; Tirzepatide is a dual GIP/GLP-1 agonist. This dual mechanism is unique among currently studied peptides and is believed to contribute to tirzepatide's observed efficacy profile in metabolic research.
Both peptides use fatty acid modifications to extend their half-lives through albumin binding, but the implementations differ:
The choice depends on the research question:
Both peptides require careful reconstitution and storage to maintain stability. If you are new to handling lyophilised peptides, start with our how-to guide series and use the reconstitution calculator to confirm dosing volumes. Always verify peptide identity and purity by reading the COA before beginning any protocol.
What is the main difference between Semaglutide and Tirzepatide?
Semaglutide is a selective GLP-1 receptor agonist, while Tirzepatide is a dual GIP/GLP-1 receptor agonist. This means Tirzepatide activates two incretin pathways simultaneously, whereas Semaglutide targets only one.
How often are Semaglutide and Tirzepatide administered in research?
Both peptides are designed for once-weekly administration due to their extended half-lives - approximately 7 days for Semaglutide and approximately 5 days for Tirzepatide.
Which peptide has stronger published metabolic data?
Published SURMOUNT trial data shows Tirzepatide at higher doses produced larger metabolic effects than Semaglutide, likely due to additional GIP pathway engagement. However, Semaglutide has more established cardiovascular outcomes data from the SELECT trial.
New-U Peptides stocks both Semaglutide and Tirzepatide in 10-vial packs, verified by Janoshik and Freedom Diagnostics.
Shop Now